Literature DB >> 6404407

Agranulocytosis associated with malaria prophylaxis with Maloprim.

G Friman, C Nyström-Rosander, G Jonsell, A Björkman, G Lekås, B Svendsrup.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404407      PMCID: PMC1547237          DOI: 10.1136/bmj.286.6373.1244

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  4 in total

Review 1.  Adverse effects of dapsone.

Authors:  W R Graham
Journal:  Int J Dermatol       Date:  1975-09       Impact factor: 2.736

2.  Why agranulocytosis from dapsone?

Authors:  W H Jopling
Journal:  Ann Intern Med       Date:  1972-07       Impact factor: 25.391

3.  Agranulocytosis due to dapsone.

Authors:  A J Ognibene
Journal:  Ann Intern Med       Date:  1970-04       Impact factor: 25.391

4.  In vitro inhibition of granulopoiesis by 4-amino-4'-hydroxylaminodiphenyl sulfone.

Authors:  R M Weetman; L A Boxer; M P Brown; N M Mantich; R L Baehner
Journal:  Br J Haematol       Date:  1980-07       Impact factor: 6.998

  4 in total
  13 in total

1.  Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain.

Authors:  P A Phillips-Howard; L J West
Journal:  J R Soc Med       Date:  1990-02       Impact factor: 5.344

Review 2.  Risks and benefits of prophylactic antimalarial drugs.

Authors:  A Breckenridge
Journal:  BMJ       Date:  1989-10-28

Review 3.  Efficacy of drug prophylaxis.

Authors:  P A Phillips-Howard
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

Review 4.  Drug-induced agranulocytosis.

Authors:  H Heimpel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

5.  Malaria deaths in visitors to Canada and in Canadian travellers: a case series.

Authors:  K C Kain; D W MacPherson; T Kelton; J S Keystone; J Mendelson; J D MacLean
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

6.  N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.

Authors:  H J Gill; M D Tingle; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

7.  Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes.

Authors:  M D Coleman; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 8.  Adverse effects of antimalarials. An update.

Authors:  G A Luzzi; T E Peto
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606

Review 9.  Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes.

Authors:  Bernard J Brabin; Teunis A Eggelte; Monica Parise; Francine Verhoeff
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Agranulocytosis during malaria prophylaxis with Maloprim (pyrimethamine and dapsone).

Authors:  F Booth; L C Barker; C J Barton; R B Naik
Journal:  Postgrad Med J       Date:  1984-08       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.